Increasing your dose before your body has acclimated increases the risk of side effects including nausea, vomiting, and GI discomfort
Patients should be instructed to report new or worsening abdominal pain, persistent nausea or vomiting, or changes in bowel habits, as these could represent medication side effects, autoimmune disease activity, or serious complications such as pancreatitis
Amongst randomized patients who already lost 5% body weight during the 12-week intensive lifestyle lead-in period, subsequent treatment with ZEPBOUND resulted in a statistically significant reduction in body weight compared to placebo from randomization (Week 0) to Week 72
Some insurance plans may cover Mounjaro for an FDA-approved indication, while others may require documentation, step therapy or prior authorization
Reported issues include dosing errors and quality/handling problems (FDA safety communication, updated 2025)
The key is supporting your skin so it can adapt in a healthy, balanced way while you continue your weight loss journey